Currently FDA-Approved COX-2 Inhibitors
Celecoxib (Celebrex) is the only COX-2 selective inhibitor currently approved and available on the U.S. market. 1
Historical Context
The COX-2 inhibitor landscape has dramatically changed since the mid-2000s due to cardiovascular safety concerns:
Withdrawn from Market:
- Rofecoxib (Vioxx) - Voluntarily withdrawn by Merck in September 2004 due to increased risk of heart attack and stroke 1
- Valdecoxib (Bextra) - Received FDA black box warning in December 2004 for use in coronary artery bypass graft surgery, subsequently withdrawn 1
Never Approved in the United States:
- Etoricoxib (Arcoxia) - Available in Europe but not FDA-approved 2, 3, 4
- Lumiracoxib (Prexige) - Available in some countries but not FDA-approved 2, 3
- Parecoxib (Dynastat) - Injectable prodrug of valdecoxib, not FDA-approved 5, 6
Current Status of Celecoxib
Celecoxib remains on the market with a black box warning emphasizing increased cardiovascular risk, particularly with prolonged use and higher doses. 1 The FDA Advisory Committee in February 2005 unanimously concluded that celecoxib significantly increases cardiovascular event risk in a dose-dependent manner but recommended it remain available under strict conditions including:
- Black box warning on labeling
- Restrictions on direct-to-consumer advertising
- Patient medication guides
- Use of lowest effective dose for shortest duration necessary 1
Important Clinical Caveat
All NSAIDs, whether COX-2 selective or nonselective, now carry similar FDA warnings regarding cardiovascular, gastrointestinal, renal, and skin adverse effects. 7 The distinction between COX-2 inhibitors and traditional NSAIDs has been largely eliminated from a regulatory warning perspective, though celecoxib retains some gastrointestinal safety advantages over nonselective NSAIDs. 5, 8